(Alliance News) - Medica Spa announced Thursday that it has received 510k clearance from the U.S. FDA, through its subsidiary Tecnoideal America Inc, to market hemoconcentrators, manufactured by Medica, in the U.S. market, with the indication of use on adult patients, for the removal of excess fluid from the blood, for the purpose of restoring physiological blood conditions during or at the end of cardiopulmonary bypass surgery.

President Luciano Fecondini comments, "FDA clearance for the marketing of hemoconcentrators opens up important commercial opportunities for Medica Group, given the importance of the U.S. market in both strategic and geographic terms. Hemoconcentrators represent only the first class of approved devices; the FDA clearance process is already underway for a number of other devices in Medica's product portfolio."

Medica's stock on Thursday closed 2.4 percent in the red at EUR16.30 per share.

By Chiara Bruschi, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.